Cardiovascular News

Invasive strategy does not reduce risk of cardiovascular death or non-fatal MI in older NSTEMI patients   Presenting the results of the study, the largest of its kind in this population, at the 2024 European Society of Cardiology (ESC) congress, study chair and chief investigator Vijay Kunadian (Translational and Clinical Research Institute, Newcastle University and Freeman Hospital, Newcastle-Upon-Tyne, UK) said that though the invasive strategy did not reduce the primary endpoint, it did appear to be safe overall in older patients. #Bestof2024 Read more: https://lnkd.in/eyT5Cx_C

Which were the stories that captured the attention of the Cardiovascular News readership in 2024? Find out in our run-down of the top 10 most-read articles of the year. https://lnkd.in/ee_rQVK3

DCB is an effective option for PCI in patients with diabetes Diabetes is one of the strongest risk factors for coronary disease, Pedro Lemos (Hospital Israelita Albert Einstein, São Paulo, Brazil) tells Cardiovascular News, discussing his strategies for managing the treatment of diabetic patients in the cath lab. Read more: https://lnkd.in/gCaUx8Cb #ProvenPerformers #SeQuentDCBs #DrugCoatedBalloons This post is sponsored by B. Braun Group

New evidence suggests fasting not needed before cardiac catheterisation procedures David Ferreira (John Hunter Hospital, Newcastle, Australia) presented findings of the SCOFF trial at the 2024 European Society of Cardiology (ESC) Congress (30 August–2 September, London, UK), where he argued that these results, alongside other existing evidence from studies such as CHOW-NOW, TONIC and Fast-CIED, should open the discussion about changes to guidelines recommending fasting as standard before cardiac catheterisation. #Bestof2024 Read more: https://lnkd.in/eZhj7kZR

PCI should be standard of care in patients with coronary artery disease undergoing valve replacement   Performing percutaneous coronary intervention (PCI) significantly improved outcomes in patients with stable coronary artery disease (CAD) and severe aortic stenosis selected for transcatheter aortic valve implantation (TAVI), results of the NOTION-3 trial have shown. #Bestof2024 Read more: https://lnkd.in/exHu6CBz

JenaValve Technology, Inc. Technology has announced the completion of the first patient procedure for inclusion in the JENA-VAD registry, evaluating the ability of the Trilogy system to treat severe symptomatic aortic regurgitation safely and effectively in patients with a continuous flow left ventricular assist device https://lnkd.in/efqtX7h9

The first round of finalists for the second Global Cardiovascular Awards has been revealed. Click on the link to view the initial shortlist announcement. Medtronic RAMPART ic Egg Medical Siemens Healthineers ORSIF SYNDEO Medical British Heart Foundation Global Heart Hub TRiCares GmbH Boston Scientific Innvolution Healthcare Private Limited HeartFlow, Inc Arineta Elixir Medical Corporation BIOTRONIK https://lnkd.in/gGpS_tD4

The US FDA has expanded the indications for the Johnson & Johnson Impella 5.5 and Impella CP heart pumps, granting premarket approval for use in specific paediatric patients with symptomatic acute decompensated heart failure and cardiogenic shock https://lnkd.in/ee4CnueZ

Protaryx Medical has announced the completion of its first-in-human (FIH) study, assessing its advanced transseptal puncture technology

Capstan Medical has announced the successful closing of an oversubscribed US$110 million Series C, which will support it bringing its robotic structural heart solution to market. https://lnkd.in/ekPHx-n6